Videos
John Edwards, CEO of Drusolv Therapeutics, lays out the company’s plan to use statins as a treatment for intermediate AMD. The firm is based off…
Read MoreRemis Bistras, CEO of ProFarma, lays out the company’s plan to improve the delivery and effective life of drugs that strengthen neuroprotectiveness in retina ganglion…
Read MoreShelley Boyd, MD, president and chief scientific officer, says Translatum Medicus Inc. has raised its first angel round based upon the potential of the company’s…
Read MoreJohn Freshley, president and CEO of ONL Therapeutics, updates OIS on the development program of Fas inhibitors. The company’s lead product is ONL 1204, which…
Read MoreReenie McCarthy, CEO of Stealth BioTherapeutics, introduces the company’s early-stage clinical program testing mitochondrial medicine as treatment for ophthalmic conditions. McCarthy details three ongoing clinical…
Read MoreJoseph Gardner, president and CEO, introduces the company’s first-in-class pipeline targeting the Tie2/VE-PTP pathway. Gardner delivers an extensive overview of Aerpio’s AKB-9778, a novel small…
Read MoreJason Slakter, MD, CEO, lays out a pivotal year for Ohr Pharmaceutical’s squalamine lactate, an intracellular treatment for wet AMD. Dr. Slakter reviews early results…
Read MoreOIS@ASRS co-chairs Emmett Cunningham Jr., MD, Mark S. Humayun, MD, PhD, and John Pollack, MD, took a few minutes to share their thoughts on the…
Read MoreCandor, passion, realism, talent, flexibility, self awareness, humility, and focus are all qualities seed-stage benefactors look for in a start-up founder, fund managers said at…
Read MoreDeb Jorn, EVP, corporate development, shares promising results from three clinical trials of the company’s Durasert delivery product. She also shares pSivida’s plans to file…
Read MoreDan Myers, CEO, discusses the promise and challenges facing the Alimera’s development of Illuvien for the treatment of DME. He shares results from the firm’s…
Read MoreCasey Kopczynki, PhD, chief scientific officer, shares how Aerie is applying 12 years of studying Rho kinase to combat retinal disease, including AMD and DR.…
Read MoreSUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.